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smaller fractions have been safely performed. This means 
that the facility can be operated more efficiently in CIRT, 
permitting treatment for a larger number of patients than is 
possible with other modalities over the same period of time. 
In 2010, a new treatment facility with three rooms was 
completed with the beam lines being extended from the 
existing accelerators, in which CIRT with a pencil beam 
scanning became available. Recently, we have successfully 
begun treatment of moving organs using respiratory-gated 
irradiation with a pencil beam scanning.  At the new facility 
a compact rotating gantry was constructed with its 
commissioning to be finished in the spring of 2016.  
In order to exchange information and perform a prospective 
study for CIRT, we have recently established J-CROS (Japan 
Carbon-ion Radiation Oncology Study Group). Under the 
framework of J-CROS, we will conduct multi-institutional 
studies on such tumors as head and neck tumors, NSCLC 
(mainly T2 tumors), hepatoma, pancreas cancer, post-
operative recurrence of rectal cancer, and bone & soft tissue 
sarcoma. These tumors are chosen based on the recognition 
that therapeutic techniques have not yet been fully 
established and treatment outcome should be further 
improved, as well as that reproducibility of NIRS clinical 
results should be evaluated by other groups. The J-CROS 
study will also include the study producing benchmark results 
in selected tumors, as well as a randomized study comparing 
CIRT with PBT or photon therapy.  
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Purpose: The aim of the present Monte Carlo study is to 
evaluate the variation of energy deposition in healthy tissues 
in the human eye which is irradiated by brachytherapy 
sources in comparison with the resultant dose increase in the 
gold nanoparticle (GNP)-loaded choroidal melanoma.  
Material and method: The effects of these nanoparticles on 
normal tissues are compared between 103 Pd and 125I as two 
ophthalmic brachytherapy sources. Dose distribution in the 
tumor and healthy tissues has been taken into account for 
both mentioned brachytherapy sources. Also, in certain 
points of the eye, the ratio of the absorbed dose by the 
normal tissue in the presence of GNPs to the absorbed dose 
by the same point in the absence of GNPs has been 
calculated. In addition, differences of  the absorbed dose in 
the tumor observed in the comparison of simple water 
phantom and actual simulated human eye in presence of 
GNPs are also a matter of interest that have been considered 
in the present work.  
Result and conclusion: The difference between the eye globe 
and the water phantom is more obvious for 125I than that of 
the 103 Pd when the ophthalmic dosimetry is done in the 
presence of GNPs. Whenever these nanoparticles are utilized 
in enhancing the absorbed dose by the tumor, the use of 125I 
brachytherapy source will greatly amplify the amount of dose 
enhancement factor (DEF) in the tumor site without inflicting 
much damage to healthy organs, when compared to the 103 Pd 
source. Furthermore in Monte-Carlo studies of eye 
brachytherapy, more precise definition of the eye phantom 
instead of a water phantom will become increasingly 
important when we use 125I as opposed to when 103 Pd is 
considered. 
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Purpose: The emphasis of the present work is to compare the 
effects of gold nanoparticles (AuNPs) on healthy human 
ocular tissues in ophthalmic brachytherapy dosimetry, 
between water and eye phantoms by utilization of the two 
most noteworthy Monte-Carlo codes of GEANT4 and MCNP5. 
Material and method: The intended study was based upon a 
simulated model of the human eye consisting different parts 
such as Lens, Cornea, retina, Choroid, Sclera, skull bone, 
Anterior Chamber and a melanoma tumor which was latticed 
to house AuNPs required for the dosimetry comparisons of 
two uniquely defined radionuclides of 125I and 103Pd. The 
effects of the presence of AuNPs on the absorbed dose by the 
tumor have been taken into account using both Monte-Carlo 
codes mentioned above; furthermore, the aberrations in dose 
calculations of the simple eye phantom and the realistic eye 
model were also an element of consideration. The 
importance of such evaluations on various compositions that 
are most common in Monte Carlo studies could prove to be 
rewarding, especially in presence of external anomalies such 
as AuNPs.  
Result and Conclusion: With respect to the numerous 
distinctions between codes themselves, it is always fruitful to 
compare multiple of these programs with one another; 
hence, a rigorous inspection of the results has been 
executed, and dissimilarities have been highlighted for better 
understanding of the advantages and deficiencies of both 
codes. All in all, it is best stated that interdisciplinary 
methods of combining diverse therapeutic applications have 
gained much ground in our current era, and serve to 
significantly increase efficiency of cures worldwide.  
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Purpose: A method to decrease the risk of rectal toxicity 
during prostate radiotherapy treatments consists of an 
implantation of a rectum spacer (RS). Nevertheless the 
implantation of a RS is expensive and invasive. Therefore a 
decision support system to identify a priori whether a 
specific patient would benefit from a RS would be very 
beneficial. 
We have developed a novel method to predict the CT images 
with a ‘virtual’ RS based on a CT scan without RS. Predictions 
of the gain of dose, and consequently of toxicity reduction 
can be obtained through a validated multifactorial 
nomogram.  
Materials/methods: A patient dataset consisting of 16 
prostate cancer patients with CT imaging prior and after a 
gel RS implantation (SpaceOAR™ System, Augmenix Inc.) was 
used. The median inserted gel volume was 10.5 cc. Gel 
contours of the first 8 patients were used as a training set to 
derive the spatial deformation model of the RS.  
A deformation model of the RS was build, based on 
overlapping volumes of RS’s of different patients with a 
probability of >3 contour corresponded with a volume of 10 
cc. From this model, a deformation field was calculated that 
mimics the expansion of the RS between the prostate and the 
rectum. The CT images of the remaining 8 patients were used 
to validate the virtual RS model, for this the distance 
between the rectum and the prostate was compared for the 
virtual RS and the actual RS. For one patient the dose was 
planned on all 3 CT’s (no, real and virtual spacer) according 
to our clinical practice (70 Gy: 28 x 2.5 Gy). We used a 
validated multifactorial nomogram developed for predicting 
acute and late radio-induced rectal toxicities. 
Results: The average minimum distances between the 
prostate and rectum of all 8 patients in the validation set 
increased with 3.7±2.4 (1SD) mm when the virtual RS was 
applied. For the real RS the average increase in minimum 
distance was 5.4±2.7 mm. The mean distances between the 
prostate and rectum without RS was 15.8±3.2 mm, with the 
virtual RS this was 19.5±3.3 mm comparable to the real RS 
22.0±4.3 mm. 
For one patient the planned dose on all 3 CT’s is shown in the 
table and figure.  
The virtual spacer revealed a large decrease in volume 
receiving more than 65 Gy, which however correlated in no 
significant difference of predicted late toxicity. 
 
 
 
 
 
Conclusions: We have developed a novel method to simulate 
a prostate-rectum spacer that is a useful tool to identify 
patients with a potential dose and outcome benefit of a RS 
implantation. The volume of the virtual RS can be estimated 
through the use of different deformation fields. For the 
presented patient the RS would not give a clinical benefit, so 
this patient should not get a RS. We envision that in the 
future this virtual spacer–based decision support system will 
be used to quantify a priori the potential benefit of such 
approach, more particularly before extremely 
hypofractionated schedules.  
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Purpose: Terbium is a unique element as it provides a 
quadruplet of radionuclides suited for diagnostics and 
therapy in nuclear medicine [1]. As part of the PSI-ISOLDE 
collaboration, we concentrated on the collection and 
purification of 149Tb (α-emitter, T1/2 = 4.1 h – for potential 
therapy) and 152Tb (β+-emitter, T1/2 = 17.5 h – for use in PET 
imaging), for significant imaging and therapy investigations.  
Materials/methods: Mass-separated beams of 149Tb and 152Tb, 
respectively, were implanted at ISOLDE-CERN into Zn-coated 
Au foils. With 1.5 hours of collection and 2 hours decay of co-
implanted activities, up to 200 MBq 149Tb could be 
transported to PSI. Collections of 152Tb lasted 4 to 6 hours 
and up to 2 GBq 152Tb could be shipped to PSI. 
The Tb radionuclides were extracted from the Zn foils by 
dissolving them in HNO3/NH4NO3, loaded on to a macroporous 
strongly acidic cation exchange resin and the Tb 
radionuclides eluted using dilute α-hydroxyisobutyric acid (α-
HIBA).  The product eluent was used directly for the 
radiolabeling process. 
Complementing previous therapy studies with 149Tb-folate 
and 161Tb-folate [2, 3], we focused on the possible side 
effects of such a treatment. Healthy mice, without tumors, 
were injected with increasing activity levels to investigate 
kidney damage after α-therapy with 149Tb-folate and compare 
it with the damage caused by 161Tb-folate-based β-therapy. 
These mice are monitored with regard to potential undesired 
side effects. DOTANOC and DOTA-RGD were also labelled 
with 152Tb, a radionuclide which can potentially be used for 
PET imaging. They were injected into AR42J and U87MG 
tumor-bearing mice, which were imaged using a benchtop 
small animal PET/CT scanner (Genisys8, Sofie Biosciences). 
Results: The 149Tb and 152Tb were effectively separated from 
Ce, Pr, Ba and La, yielding a radionuclidically pure product.  
The product in question was successfully labelled to 
DOTANOC and DOTA-RGD at high specific activity of up to 10 
MBq/nmol and radiochemical purity of >95%. The 149Tb-folate 
dose escalation study was conducted with six mice injected 
